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ABSTRACT 
The vast majority of coding variants are rare, and assessment of the contribution of rare variants 
to complex traits is hampered by low statistical power and limited functional data. Improved methods for 
predicting the pathogenicity of rare coding variants are needed to facilitate the discovery of disease 
variants from exome sequencing studies. We developed REVEL (Rare Exome Variant Ensemble 
Learner), an ensemble method for predicting the pathogenicity of missense variants based on individual 
tools: MutPred, FATHMM, VEST, Polyphen, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, 
GERP, SiPhy, phyloP, and phastCons. REVEL was trained using recently discovered pathogenic and 
rare neutral missense variants, excluding those previously used to train its constituent tools. When 
applied to two independent test sets, REVEL had the best overall performance (p<10-12) compared with 
any individual tool and seven ensemble methods: MetaSVM, MetaLR, KGGSeq, Condel, CADD, DANN, 
and Eigen. Importantly, REVEL also had the best performance for distinguishing pathogenic from rare 
neutral variants with allele frequencies <0.5%. Compared with other ensemble methods, the area under 
the receiver operating characteristic curve (AUC) for REVEL was 0.046-0.182 higher in an independent 
test set of 935 recent SwissVar disease variants and 123,935 putatively neutral exome sequencing 
variants, and 0.027-0.143 higher in an independent test set of 1,953 pathogenic and 2,406 benign 
variants recently reported in ClinVar. We provide pre-computed REVEL scores for all possible human 
missense variants to facilitate the identification of pathogenic variants in the sea of rare variants 
discovered as sequencing studies expand in scale. 
 
INTRODUCTION 
Interpreting genetic variation from next generation sequencing (NGS) datasets is essential for 
advancing personalized medicine.1; 2 The vast majority of variants discovered by NGS are rare.3; 4 Recent 
exome and genome sequencing studies have found that roughly 85% of nonsynonymous variants have 
alternate allele frequencies (AF) less than 0.5%, and roughly 100-400 rare nonsynonymous variants are 
discovered per sequenced individual.3; 4 Rare coding variants play major roles in disease causation and 
may contribute to the missing heritability from genome-wide association studies.5; 6 However, the majority 
of nonsynonymous variants discovered by NGS have unknown significance because experimental 
validation of large numbers of rare variants is infeasible and association studies require prohibitively large 
sample sizes to detect rare variants with modest effect sizes with high statistical power. Therefore, 
computational tools that can accurately predict the pathogenicity of rare variants are needed to help 
identify those variants that are most likely to cause disease. 
Many tools for predicting the pathogenicity of missense variants have been developed based on 
features such as amino acid or nucleotide conservation and biochemical properties of the amino acid 
substitutions.7-18 However, individual tools often disagree, in part because they utilize different predictive 
features. Ensemble methods that combine the results of multiple individual predictors can improve 
performance.19-28 However, few existing pathogenicity prediction tools have targeted the interpretation of 
 4 
rare variants.24 Current tools are often trained on predominantly common neutral variants and some 
explicitly impose a minimum AF threshold for defining neutral training variants15; 21; 25. In contrast, most 
disease training variants are rare. As a result of this AF imbalance between disease and neutral training 
variants, tools that rely on AF as a predictive feature may have lower ability to distinguish disease 
variants from rare neutral variants than from common ones.24 Biological differences such as higher 
conservation scores for rare versus common variants may also make rare neutral variants more difficult to 
distinguish from disease variants.24; 29 Despite the fact that the vast majority of nonsynonymous variants 
discovered by NGS are rare, the performance of existing prediction tools on rare variants is not well 
known.30 Thus, there is a growing need for the development and evaluation of tools for predicting the 
pathogenicity of rare variants.  
Here, we present an ensemble method for predicting the pathogenicity of missense variants that 
outperforms existing approaches overall and when applied to rare variants. The Rare Exome Variant 
Ensemble Learner (REVEL) method incorporates recently developed individual prediction tools as 
features and was trained on recently discovered disease and rare neutral missense variants that did not 
overlap with the training data for its constituent predictors. We also assembled two large independent test 
sets of recently discovered pathogenic and benign variants that parallel the likely application of REVEL to 
newly discovered variants from NGS studies. We benchmark the performance of REVEL and existing 
ensemble predictors for distinguishing disease mutations from neutral variants across a broad range of 
allele frequencies. To make our method easily accessible for research and clinical use, we provide pre-
computed REVEL scores for all possible human missense variants31. 
 
METHODS 
Random forest. We trained a random forest on the set of variants described below using the R 
‘randomForest’ package32 with 1000 binary classification trees33; 34. We selected the number of trees to be 
sufficiently large for the out-of-bag (OOB) error rate to plateau; sensitivity analyses showed that 
increasing the number of trees to 3000 did not improve performance on the training dataset. The OOB 
prediction for a given training variant is the proportion of trees that classified the variant as pathogenic 
across only those trees in the forest that excluded the variant from their bootstrapped training sample.33 
Four features were selected at random as candidates for each split in the random forest trees, which was 
the default value for 18 features described below. To address the imbalance in the numbers of available 
disease and neutral training variants, we sampled the same number (n = 6,182) of disease and neutral 
variants when generating the bootstrapped training set for each tree in the forest. The importance of each 
predictive feature was measured by the total decrease in the Gini index33 (improvement in node purity) for 
all splits on that feature, averaged over all trees in the forest. 
Training variants. REVEL was trained using putative disease and rare neutral missense 
variants. Disease variants were obtained from the Human Gene Mutation Database (HGMD)35 version 
2015.2 and were restricted to the set of missense Disease Mutations (DMs) added to HGMD since 
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August 1, 2012 to minimize overlap with variants previously used to train component features in the 
REVEL random forest. Exome sequencing variants (ESVs) were obtained from the Exome Sequencing 
Project (ESP)4 European-American and African-American populations; Atherosclerosis Risk in 
Communities (ARIC) study36 European-American and African-American populations; and 1000 Genomes 
Project (KGP)3 European, Yoruban, and Asian populations, as recorded in dbNSFP31 version 2.7. After 
excluding all disease variants in HGMD and the data sources for test sets 1 and 2 described below, the 
remaining ESVs were considered putatively neutral. For both the disease and neutral training variants, we 
also excluded all variants that had previously been used to train individual component features in the 
REVEL random forest; specifically, MutPred8, Polyphen-210, MutationTaster11, FATHMM v2.314, and 
VEST 3.015. Finally, when a given genetic variant corresponded to multiple amino acid substitutions 
(AASs) at the protein level, only one AAS was selected at random. After applying all exclusion criteria, a 
total of 6,182 disease variants and 281,972 putatively neutral ESVs remained. We randomly selected 
approximately half (n=140,921) of the putatively neutral ESVs, of which 123,706 rare ESVs (with a 
maximum alternate AF between 0.1% and 1% across the seven study populations) were used for training, 
and 17,215 ESVs with AF >1% were used for initial evaluation of performance across a range of AFs. The 
remaining half of ESVs were held out for use as independent test variants as described below. Thus, the 
final training set consisted of 6,182 HGMD disease variants and 123,706 rare neutral ESVs. 
Features. REVEL incorporates a total of 18 individual pathogenicity prediction scores from 13 
tools as predictive features. MutPred scores were newly computed for this study using the UniProt37 
canonical protein sequence when available and the Ensembl38 canonical transcript otherwise. 
PROVEAN13 scores were obtained from dbNSFP v2.9 (February 3, 2015). Sixteen additional scores were 
obtained from dbNSFP v2.7 (September 12, 2014), including eight functional prediction scores (SIFT7; 
Polyphen-2 HVAR and HDIV; LRT9; MutationTaster; MutationAssessor12; FATHMM v2.3; and VEST 3.0) 
and eight conservation scores (GERP++39; SiPhy40; three phyloP41 scores for primates, placental 
mammals, and vertebrates; and three phastCons42 scores for primates, placental mammals, and 
vertebrates). For PolyPhen-2, FATHMM, and PROVEAN, when multiple protein isoforms were associated 
with a given variant, we used the average score across all isoforms. Missing features were imputed using 
the k-nearest neighbors method implemented in the R ‘impute’ package43. Missing feature values for a 
given variant were assigned the average value of the non-missing elements of its k = 40 nearest 
neighboring variants; when more than 50% of features were missing for a given variant, we assigned the 
overall mean across all variants. 
Test sets. We assembled two independent test sets that did not overlap with either the REVEL 
training data or the training data for the component features of REVEL. Test set 1 consisted of 935 
disease variants added to SwissVar44 (release 2015_10) since August 1, 2012 and approximately half (n 
= 141,051) of the putatively neutral nonsynonymous ESVs described above that had not been included in 
the REVEL training set or initial evaluation. Test set 2 consisted of 1,953 pathogenic or likely pathogenic 
and 2,406 benign or likely benign variants recently deposited into ClinVar45; 46 by submitters following 
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variant classification guidelines similar to the American College of Medical Genetics and Genomics 
(ACMG) guidelines47; 48. Specifically, all single nucleotide missense variants submitted to ClinVar by 
GeneDx, Emory Genetics Laboratory, Partners HealthCare Laboratory for Molecular Medicine49, 
University of Chicago Genetic Services Laboratory, Ambry Genetics, and Invitae were downloaded on 
October 13, 2015. We excluded the following from both test sets 1 and 2: all REVEL training variants, all 
DM variants added to HGMD prior to August 1, 2012, and all variants that had previously been used to 
train individual component features in REVEL. Finally, to eliminate overlap between the two test sets, we 
excluded any variants that were present in both SwissVar and ClinVar from test set 1 if benign (n=9) and 
from test set 2 if pathogenic (n=12). 
Comparators. We compared the performance of REVEL to seven ensemble prediction tools that 
were recently developed, widely used, and readily implemented: MetaLR28, MetaSVM28, Eigen50, CADD16 
v1.3, DANN17, Condel19, and KGGSeq23; 24 v0.8. We ran KGGSeq using the default model selection 
option that chooses an optimized set of features for each variant24. We plotted receiver operating 
characteristic (ROC) curves and compared the area under the ROC curve (AUC) estimates for different 
tools using Delong's test51 implemented in the R ‘pROC’ package52. We also computed the area under 
precision-recall (PR) curve using the R ‘ROCR’ package53. For the training variants, REVEL scores were 
computed using only the OOB predictions, which have been shown to provide performance estimates that 
are as accurate as for an independent test set of equal size consisting of variants with similar 
characteristics33. 
 
RESULTS 
Characterization of REVEL features. The REVEL ensemble score combines pathogenicity 
predictions from 18 individual scores (features), including eight conservation scores and 10 functional 
scores. Figure 1A shows the correlation among individual features. The conservation scores, as well as 
LRT and Mutation Taster, were almost all highly (Spearman rank correlation coefficient, R > 0.6) to 
moderately correlated (0.4 < R < 0.6). Five functional scores (MutationAssessor, PROVEAN, VEST, 
Polyphen-2 HDIV and HVAR) were almost all highly correlated. VEST was also highly correlated with 
several conservation scores, LRT and MutationTaster. In contrast, FATHMM had low correlation (R < 0.4) 
with all other scores, and MutPred and SIFT had low to moderate correlation with other scores. The five 
most important features in the REVEL random forest were: FATHMM, VEST, MutationAssessor, MutPred, 
and Polyphen-2 HVAR (Figure 1B). The importance measure for an individual feature reflects 
correlations with other features as well as its intrinsic predictive ability, because importance may be 
shared among correlated features34. 
Overall performance of REVEL compared with other methods. The REVEL ensemble score 
discriminated well between HGMD disease mutations and putatively neutral ESVs, with an overall AUC of 
0.908 estimated using OOB predictions for the training set (Figure 2A). The AUC for REVEL was 
significantly better than any of its constituent features (maximum p < 10-12 for any pairwise comparison), 
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among which VEST (AUC = 0.844) and FATHMM (AUC = 0.824) had the highest AUCs (Table S1). 
AUCs for the other individual prediction tools ranged from 0.589 to 0.809, and tended to be higher for 
functional predictors (0.717-0.844) than for conservation scores (0.589-0.791). The AUC for REVEL was 
also significantly better than the other ensemble methods (maximum p < 10-12 for any pairwise 
comparison), among which MetaLR (AUC = 0.883) and MetaSVM (AUC = 0.879) had the next highest 
AUCs (Figure 2A; Table S2).  
Performance for rare versus common neutral variants. We next compared the performance of 
REVEL to that of other ensemble methods for discriminating between HGMD disease mutations, which 
are predominantly rare, and putatively neutral ESVs with AFs ranging from very rare (0.1-0.3%) to 
common (>5%). We found that all of the ensemble methods tended to have worse ability to discriminate 
disease mutations from rare neutral variants than from common neutral variants (Figure 2B; Table S2). 
However, compared to other ensemble methods, REVEL had superior discriminatory ability for neutral 
variants within all AF ranges up to 3%, with the greatest improvements in AUC for rare variants with AF < 
0.5% (Figure 2B; Table S2). For neutral variants with AF > 3%, REVEL had the second highest AUC 
after MetaLR. In addition, the performance of REVEL appeared to be less sensitive to neutral variant AF 
than other methods. The AUC range for very rare to common variants was narrowest for REVEL (0.897 to 
0.957) and widest for DANN (0.703 to 0.897), which appeared to be most sensitive to AF (Table S2). 
Performance evaluation in two independent test sets. In test set 1, consisting of 935 
independent disease mutations from SwissVar and 141,051 putatively neutral ESVs, the relative 
performance of all eight ensemble predictors (Figure 3; Table S3) was similar to that observed in the 
training set. REVEL had the best performance both overall (p < 10-12) and for neutral variants within all AF 
ranges up to 5%. For common neutral variants with AF > 5%, REVEL was again surpassed only by 
MetaLR. The improvement in AUC obtained using REVEL versus the other ensemble methods was again 
greatest for rare neutral variants. In test set 2, consisting of 1,953 pathogenic and 2,406 benign variants 
from ClinVar, we confirmed that REVEL had the best performance among the ensemble methods both 
overall (p < 10-12) and for neutral variants within all AF ranges up to 3%, and that the improvement in AUC 
was greatest for rare neutral variants (Figure 4; Table S4). All of the ensemble methods had better 
overall ability to distinguish benign vs. pathogenic variants from ClinVar, than putatively neutral ESVs vs. 
disease variants from SwissVar or HGMD, which may be a consequence of the more stringent definition 
of benign variants from ClinVar. REVEL also had the best overall performance measured by the area 
under the PR curve (Table S5) across a wide range of proportions of disease variants represented in the 
training set (4.8%), and test sets 1 (0.7%) and 2 (44.8%). 
Interpretation of REVEL scores. The REVEL score for an individual variant can range from zero 
to one, reflecting the proportion of trees in the random forest that classified the variant as pathogenic. 
REVEL score distributions for the 6,182 HGMD disease and 123,706 putatively neutral ESV training 
variants, and for all 1,125,160 ESVs reported by ESP, ARIC and KGP, are shown in Figure 5a. The 
distributions of REVEL scores were very similar for all reported ESVs and the subset of putatively neutral 
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ESV training variants, with only a small shift towards higher scores for all ESVs. Figure 5b shows the 
percentiles of the REVEL scores separately for disease and neutral training variants or all ESVs. Figure 
S1 shows the sensitivity and specificity corresponding to different REVEL score thresholds, above which 
a variant would be classified as pathogenic. For example, 75.4% of disease mutations but only 10.9% of 
neutral variants (and 12.4% of all ESVs) have a REVEL score above 0.5, corresponding to a sensitivity of 
0.754 and specificity of 0.891. Selecting a more stringent REVEL score threshold of 0.75 would result in 
higher specificity but lower sensitivity, with 52.1% of disease mutations, 3.3% of neutral variants, and 
4.1% of all ESVs being classified as pathogenic.  
 
DISCUSSION 
REVEL is an ensemble method for predicting the pathogenicity of rare missense variants. Rare 
variants are likely to comprise the vast majority of variants of unknown significance discovered in future 
sequencing studies. We have shown that REVEL consistently has the best overall performance 
compared to existing methods, particularly for distinguishing disease mutations from uncommon neutral 
missense variants with an AF below 3%. To facilitate use by clinicians and researchers, we have pre-
computed REVEL scores for all missense variants in dbNSFP 2.7, a database of all potential 
nonsynonymous single nucleotide variants in the human genome. REVEL thus addresses the need for a 
pathogenicity prediction tool with improved accuracy for interpreting rare genetic variants. 
The REVEL method has several strengths. First, REVEL was trained and tested on recently 
identified disease and neutral variants that may closely resemble novel variants discovered by future 
NGS studies, which are likely to include variants with lower allele frequencies and more modest effects 
than previously discovered variants. The REVEL neutral training variants were specifically restricted to 
AFs between 0.1% and 1% to improve performance when interpreting rare variants. Second, REVEL 
incorporates a larger number of individual predictors than prior ensemble methods, including both 
MutPred and VEST, which were among the most important features in the REVEL random forest. 
MutPred scores, in particular, were not previously widely available and have now been computed for all 
missense variants in dbNSFP 2.7 as part of this study. Finally, we carefully removed from the training and 
test sets all variants used to train any of the component predictors in REVEL to reduce overfitting and 
inflated performance estimates. 
A key limitation of this study and others is the reliance on pathogenicity assertions from existing 
databases, which may be inaccurate and incomplete. Misclassification of training and test variants as 
disease or neutral would limit both the accuracy of the prediction method and the resulting performance 
estimates. Nonetheless, we expect that the putative disease variants used to train REVEL are enriched 
for true disease variants compared to the putative neutral variants, allowing identification of key predictive 
features of pathogenic variants. An additional complication is that existing pathogenicity assertions for 
some variants may have been based in part on predictions from popular tools, such as SIFT and 
Polyphen-2, potentially resulting in inflated performance of these predictors and ensemble scores that use 
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them. Finally, the performance of REVEL and other ensemble methods is limited by the accuracy of the 
component predictors and could benefit from inclusion of additional predictors as they become available 
in the future.  
REVEL had the highest overall performance of any method in independent test sets, although its 
performance on common variants with AF > 3-5% was slightly worse than MetaLR or MetaSVM. The 
strong overall performance of REVEL reflects the fact that the majority of neutral variants in the training 
and test datasets were rare, as expected for novel variants discovered by NGS. Furthermore, while we 
carefully removed all variants used to train REVEL and its constituent features from the two test sets, we 
did not systematically exclude training variants for the comparator ensemble scores; thus the 
performance estimates for the comparators could be overly optimistic. MetaLR and MetaSVM had the 
next highest overall performance. Compared to REVEL, these two ensemble methods included many of 
the same predictive features, except for VEST, MutPred, and PROVEAN, and also included the AF, 
which could contribute to their greater sensitivity to the neutral variant AF. Condel is a weighted average 
of FATHMM and MutationAssessor, and its lower performance relative to some ensemble methods may 
be due to the inclusion of fewer predictive features. Eigen employs an unsupervised approach to separate 
variants into two classes, and also uses fewer predictive features than REVEL, MetaLR, and MetaSVM. 
CADD and DANN differ from the other ensemble methods in their use of many basic genomic and protein 
annotations from ENCODE and Ensembl as features in addition to functional predictions from Polyphen-2 
and SIFT. Although CADD and DANN did not perform as well as the other ensemble methods for 
missense variants, they have important advantages for genome-wide NGS applications because they 
provide scores for noncoding and regulatory variants that are on the same scale as for coding variants. 
The improved performance of REVEL relative to other ensemble methods was greatest for 
discriminating between disease and rare neutral variants. This result may be partly explained by the fact 
that REVEL was trained on rare neutral variants with AF <1% and did not rely on AF as a predictive 
feature. To our knowledge, one other ensemble predictor, KGGSeq24, was similarly trained on rare 
neutral variants. KGGSeq uses many of the same component predictors as REVEL, except for MutPred, 
and also includes CADD as a predictive feature. However, KGGSeq adaptively selects an optimal subset 
of features rather than using all features to predict the pathogenicity of each variant, in part to allow 
exclusion of features with missing data. Possible explanations for the improved performance of REVEL 
over KGGSeq include: use of all features for all variants by first imputing missing scores, importance of 
MutPred as a predictive feature, and use of a random forest approach rather than logistic regression. 
REVEL also outperformed its individual constituent prediction tools as expected for ensemble 
methods19-28. The top performing individual tools on our training dataset were VEST15, FATHMM14, and 
MutPred8, consistent with their high importance in the REVEL random forest. VEST predictions are based 
on a particularly large set of 86 basic genomic and protein annotations and had the best performance 
among the individual tools. FATHMM uses a hidden Markov modeling approach to analyze multiple 
sequence alignments and alignments of conserved protein domain families to compute position-specific 
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amino acid probabilities. The uniqueness of this method may contribute to the low correlation between 
FATHMM and other prediction tools and high importance in REVEL28. Finally, the strong performance of 
MutPred may be because its predictions are based on a particularly detailed model of protein structural 
and functional properties, including secondary structure, solvent accessibility, functional domains, 
methylation, phosphorylation, and glycosylation, with quantitative estimates of the probability of losing 
each property due to a particular amino acid change.  
In conclusion, REVEL is an ensemble method that outperforms existing tools for distinguishing 
disease variants from rare neutral variants. REVEL can be used to prioritize the most likely clinically or 
functionally relevant variants among the sea of rare variants that are increasingly discovered as 
sequencing studies expand in scale. For example, REVEL scores have been used by the International 
Consortium of Prostate Cancer Genetics as weights for combining variants discovered by exome 
sequencing in gene-level case-control studies. Pre-computed REVEL pathogenicity scores for all possible 
human missense variants, based on GENCODE v9 gene annotations54 for hg19, are available for 
download (see URLs). To aid interpretation, we also provide estimates of REVEL sensitivity and 
specificity for different score thresholds, and the quantiles of the REVEL score in over 1 million ESVs 
observed in KGP, ESP, and ARIC. Future studies may explore the application of REVEL to specific genes 
to evaluate its clinical utility for interpreting variants of unknown significance for a broad spectrum of 
clinical conditions. 
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FIGURE LEGENDS 
 
Figure 1. Individual prediction tools included as features in the REVEL random forest. 
(A) Correlation among the individual features ordered by hierarchical clustering. The heatmap illustrates 
the Spearman rank correlation coefficients between features computed for the REVEL training 
variants. 
(B) Relative importance of individual features. Gini importance estimates were normalized to sum to one. 
 
Figure 2. Performance of ensemble methods for discrimination of disease training variants from 
putatively neutral exome sequencing variants (ESVs). 
(A) Receiver operating characteristic (ROC) curves for 6182 HGMD disease mutations and 123,706 rare 
(AF 0.001-0.01) neutral ESVs used to train REVEL.  REVEL scores were computed using only the 
out-of-bag predictions for its training variants. 
(B) Area under the ROC curve (AUC) for 6182 HGMD disease mutations and 140,921 neutral ESVs, 
including REVEL training variants, stratified by neutral variant allele frequency. 
 
Figure 3. Performance of ensemble methods in an independent test set of SwissVar disease mutations 
and putatively neutral exome sequencing variants (ESVs). 
(A) Receiver operating characteristic (ROC) curves for 935 SwissVar disease mutations and 123,935 
rare (AF 0.001-0.01) neutral ESVs that did not overlap with the training set. 
(B) Area under the ROC curve (AUC) for 935 SwissVar disease mutations and 141,051 neutral ESVs, 
excluding REVEL training variants, stratified by neutral variant allele frequency. 
 
Figure 4.  Performance of ensemble methods in an independent test set of 1953 pathogenic and 2406 
benign variants from ClinVar. 
(A) Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) for all 
variants. 
(B) AUC for each ensemble method, stratified by neutral variant allele frequency. 
 
Figure 5. Interpretation of REVEL scores. 
(A) Distribution of REVEL scores for 6182 disease (magenta) and 123,706 neutral (cyan) training 
variants, and 1,125,160 exome sequencing variants (black). REVEL scores were computed using 
only the out-of-bag predictions for training variants. 
(B) Percentiles of the REVEL score distribution for 6182 disease (magenta) and 123,706 neutral (cyan) 
training variants, and 1,125,160 exome sequencing variants (black). REVEL scores were computed 
using only the out-of-bag predictions for training variants. 
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Figure S1.  Sensitivity and specificity for different REVEL score thresholds. 
REVEL scores were computed using the out-of-bag predictions for 6182 HGMD disease mutations and 
123,706 rare (AF 0.001-0.01) putatively neutral exome sequencing variants.  FPR = false positive rate, 
and TPR = true positive rate. 
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Table S1.  AUC of individual prediction tools in the training data and independent test sets. 
Individual prediction tool Training seta Test set 1b Test set 2c 
VEST 0.844 0.843 0.916 
FATHMM 0.824 0.787 0.804 
MutPred 0.809 0.783 0.871 
Polyphen2 HVAR 0.806 0.779 0.894 
MutationAssessor 0.806 0.785 0.885 
PROVEAN 0.799 0.792 0.891 
phyloP (vertebrate) 0.791 0.741 0.845 
Polyphen2 HDIV 0.780 0.752 0.867 
LRT 0.765 0.783 0.836 
SIFT 0.761 0.745 0.831 
SiPhy 0.742 0.728 0.781 
phastCons (vertebrate) 0.719 0.720 0.759 
MutationTaster 0.717 0.729 0.744 
GERP++ RS 0.717 0.687 0.735 
phyloP (placental) 0.701 0.675 0.743 
phastCons (placental) 0.692 0.722 0.749 
phastCons (primate) 0.647 0.691 0.679 
phyloP (primate) 0.589 0.593 0.591 
AUC = area under the receiver operating characteristic curve. 
a. The training set included 6182 novel disease mutations from HGMD, and 123,706 rare (AF 0.001-0.01) 
putatively neutral exome sequencing variants (ESVs). 
b. Test set 1 included 935 novel SwissVar disease variants and 123,935 rare (AF 0.001-0.01) putatively 
neutral exome sequencing variants (ESVs) that did not overlap with the training set. 
c. Test set 2 included 1953 pathogenic and 2406 benign variants recently reported in the ClinVar 
database. 
  
Table S2.  AUC values for discrimination of HGMD disease mutationsa from neutral exome 
sequencing variants, by neutral variant allele frequency. 
Ensemble  Neutral variant AF 
method All 0.001-0.003 0.003-0.005 0.005-0.01 0.01-0.03 0.03-0.05 >0.05 
 n=140,921 n=90,445 n=15,502 n=17,759 n=10,687 n=1925 n=4603 
REVELb 0.908 0.897 0.917 0.922 0.940 0.958 0.957 
MetaLR 0.883 0.867 0.884 0.908 0.927 0.960 0.971 
MetaSVM 0.879 0.867 0.882 0.897 0.912 0.931 0.940 
KGGSeq 0.8c 0.848 0.833 0.859 0.865 0.893 0.917 0.924 
Condel 2.0d 0.847 0.836 0.855 0.863 0.878 0.905 0.906 
Eigen 0.841 0.822 0.854 0. 864 0. 892 0.918 0.929 
CADD 1.3 0.798 0.774 0.809 0.823 0.864 0.902 0.921 
DANN 0.730 0.703 0.742 0.753 0.806 0.866 0.897 
AUC = area under the receiver operating characteristic curve. 
a. 6182 HGMD disease mutations with allele frequency distribution: 99.56% <0.01, 0.37% 0.01-0.05, and 
0.06% ≥0.05. 
b. REVEL scores were computed using out-of-bag (OOB) predictions for variants in the training set, and 
predictions from all trees in the random forest otherwise. 
c. KGGSeq scores were missing for 13 variants. 
d. Condel scores were missing for 11,491 variants. 
  
Table S3. AUC values in an independent test set of SwissVar disease mutationsa and neutral 
exome sequencing variants, by neutral variant allele frequency. 
Ensemble  Neutral variant AF 
method All 0.001-0.003 0.003-0.005 0.005-0.01 0.01-0.03 0.03-0.05 >0.05 
 n=141,051 n=90,642 n=15,273 n=18,020 n=10,458 n=1957 n=4701 
REVEL 0.893 0.880 0.902 0.908 0.929 0.951 0.954 
MetaLRb 0.849 0.830 0.849 0.877 0.900 0.947 0.967 
MetaSVMb 0.837 0.823 0.841 0.855 0.871 0.898 0.912 
KGGSeq 0.8c 0.844 0.829 0.856 0.861 0.887 0.910 0.924 
Condel 2.0d 0.804 0.792 0.813 0.818 0.839 0.864 0.879 
Eigen 0.803 0.781 0.820 0.829 0.863 0.893 0.911 
CADD 1.3 0.774 0.749 0.792 0.800 0.841 0.880 0.904 
DANN 0.726 0.698 0.741 0.752 0.803 0.857 0.890 
AUC = area under the receiver operating characteristic curve. 
a. 935 SwissVar disease mutations with allele frequency distribution: 99.68% <0.01 and 0.32% 0.01-0.05. 
b. MetaLR and MetaSVM scores were missing for 1 variant. 
c. KGGSeq scores were missing for 15 variants. 
d. Condel scores were missing for 11,642 variants. 
  
Table S4.  AUC values in an independent test set of ClinVar diseasea and neutral variants, by 
neutral variant allele frequency. 
Ensemble  Neutral variant AF 
method All <0.001 0.001-0.005 0.005-0.01 0.01-0.03 >0.03 
 n=2406 n=1224 n=417 n=364 n=288 n=113 
REVEL 0.957 0.959 0.960 0.946 0.953 0.970 
MetaLR 0.917 0.904 0.914 0.930 0.936 0.988 
MetaSVM 0.933 0.928 0.933 0.933 0.939 0.976 
KGGSeq 0.8 0.893 0.897 0.892 0.881 0.884 0.927 
Condel 2.0b 0.898 0.900 0.906 0.892 0.890 0.900 
Eigen 0.910 0.924 0.907 0.877 0.885 0.930 
CADD 1.3 0.902 0.920 0.892 0.862 0.885 0.914 
DANN 0.833 0.857 0.817 0.778 0.810 0.871 
AUC = area under the receiver operating characteristic curve. 
a. 1953 ClinVar disease mutations with allele frequency distribution: 99.95% <0.01 and 0.05% 0.01-0.05. 
b. Condel scores were missing for 84 variants. 
  
Table S5.  Area under the precision-recall curves for REVEL and other ensemble methods. 
Ensemble Training seta Test set 1b Test set 2c 
method    
REVEL 0.465 0.127 0.951 
MetaLR 0.386 0.092 0.911 
MetaSVM 0.345 0.070 0.924 
KGGSeq 0.8 0.374 0.107 0.891 
Condel 2.0 0.244 0.038 0.887 
Eigen 0.244 0.038 0.868 
CADD 1.3 0.121 0.017 0.838 
DANN 0.087 0.014 0.745 
a. The training set (4.8% disease variants) included 6182 novel disease mutations from HGMD, and 
123,706 rare (AF 0.001-0.01) putatively neutral exome sequencing variants (ESVs). 
b. Test set 1 (0.7% disease variants) included 935 novel SwissVar disease variants and 123,935 rare (AF 
0.001-0.01) putatively neutral exome sequencing variants (ESVs) that did not overlap with the training 
set. 
c. Test set 2 (44.8% disease variants) included 1953 pathogenic and 2406 benign variants recently 
reported in the ClinVar database. 
